Vertex Pharmaceuticals reported second-quarter adjusted earnings of $4.52 a share on revenue of $2.96 billion, topping Wall Street estimates of $4.26 and $2.91 billion, respectively. Sales rose 12% from a year earlier, driven by cystic-fibrosis therapies and early contributions from new launches of Casgevy, Alyftrek and Journavx. The Boston-based biotechnology company reiterated its 2025 revenue guidance of $11.85 billion to $12 billion. In its pipeline update, Vertex said a Phase 2 study of VX-993, an oral NaV1.8 inhibitor for acute pain, failed to meet its main goal, leading the company to discontinue the drug as a standalone treatment. The compound was found safe and well tolerated. Other late-stage programs, including suzetrigine for diabetic peripheral neuropathy and zimislecel for type 1 diabetes, remain on track. Separately, long-time Chief Scientific Officer David Altshuler announced plans to retire on 1 August 2026, with Senior Vice President Mark Bunnage slated to assume the role in February 2026. Despite the stronger-than-expected quarter, Vertex shares fell about 13% in post-market trading as investors reacted to the VX-993 setback.